ALK translocation renal cell carcinoma

From Libre Pathology
Revision as of 14:37, 16 December 2024 by Michael (talk | contribs)
Jump to navigation Jump to search
ALK translocation renal cell carcinoma
Diagnosis in short
LM mixed morphology, +/-papillae, +/-myxoid change
LM DDx papillary renal cell carcinoma, unclassified renal cell carcinoma, clear cell renal cell carcinoma, SMARCB1-deficient renal medullary carcinoma
IHC ALK +ve
Molecular ALK rearranagement
Grossing notes total nephrectomy for tumour grossing, partial nephrectomy grossing
Staging kidney cancer staging
Site kidney - see kidney tumours
Prevalence very rare
Treatment may respond to ALK inhibitors

ALK translocation renal cell carcinoma, also ALK-rearranged renal cell carcinoma and ALK-positive renal cell carcinoma, is a type of renal cell carcinoma recognized by the WHO.

General

  • Extremely rare.
    • One case was identified in 829 consecutively screened Korean patients.[1]
    • A second series described 8 in 276 cases on a microarray.[2]
    • In 2016, less than 17 cases reported.[3]
  • May respond to ALK inhibitors such as alectinib[4] or crizotinib.[3]

Microscopic

Features:

DDx:

IHC

Features:[6]

See also

References

  1. ↑ 1.0 1.1 1.2 Lee, C.; Park, JW.; Suh, JH.; Nam, KH.; Moon, KC. (Oct 2013). "ALK-Positive Renal Cell Carcinoma in a Large Series of Consecutively Resected Korean Renal Cell Carcinoma Patients.". Korean J Pathol 47 (5): 452-7. doi:10.4132/KoreanJPathol.2013.47.5.452. PMID 24255633.
  2. ↑ 2.0 2.1 Doğan K, Onder E (January 2024). "ALK-rearranged renal cell carcinoma (ALK-RCC): Evaluation of histomorphological and immunohistochemical features by analysis of 276 renal cell carcinoma cases in Turkey". Pathol Res Pract 253: 154951. doi:10.1016/j.prp.2023.154951. PMID 38039739.
  3. ↑ 3.0 3.1 Jeanneau, M.; Gregoire, V.; Desplechain, C.; Escande, F.; Tica, DP.; Aubert, S.; Leroy, X. (Nov 2016). "ALK rearrangements-associated renal cell carcinoma (RCC) with unique pathological features in an adult.". Pathol Res Pract 212 (11): 1064-1066. doi:10.1016/j.prp.2016.07.015. PMID 27554841.
  4. ↑ Pal, SK.; Bergerot, P.; Dizman, N.; Bergerot, C.; Adashek, J.; Madison, R.; Chung, JH.; Ali, SM. et al. (07 2018). "Responses to Alectinib in ALK-rearranged Papillary Renal Cell Carcinoma.". Eur Urol 74 (1): 124-128. doi:10.1016/j.eururo.2018.03.032. PMID 29685646.
  5. ↑ Kuroda, N.; Karashima, T.; Inoue, K.; Kasajima, A.; Ohe, C.; Kawakami, F.; Mikami, S.; Matsuura, K. et al. (Mar 2015). "Review of renal cell carcinoma with rhabdoid features with focus on clinical and pathobiological aspects.". Pol J Pathol 66 (1): 3-8. PMID 26017874.
  6. ↑ Jeanneau, M.; Gregoire, V.; Desplechain, C.; Escande, F.; Tica, DP.; Aubert, S.; Leroy, X. (Nov 2016). "ALK rearrangements-associated renal cell carcinoma (RCC) with unique pathological features in an adult.". Pathol Res Pract 212 (11): 1064-1066. doi:10.1016/j.prp.2016.07.015. PMID 27554841.
Retrieved from "https://librepathology.org/w/index.php?title=ALK_translocation_renal_cell_carcinoma&oldid=53359"